Literature DB >> 23280764

MYCN is recruited to the RASSF1A promoter but is not critical for DNA hypermethylation in neuroblastoma.

Jessica Charlet1, Marianna Szemes, Karim T A Malik, Keith W Brown.   

Abstract

Tumor suppressor genes such as RASSF1A are often epigenetically repressed by DNA hypermethylation in neuroblastoma, where the MYCN proto-oncogene is frequently amplified. MYC has been shown to associate with DNA methyltransferases, thereby inducing transcriptional repression of target genes, which suggested that MYCN might play a similar mechanistic role in the hypermethylation of tumor suppressor genes in neuroblastoma. This study tested that hypothesis by using co-immunoprecipitation and ChIP to investigate MYCN-DNA methyltransferase interactions, together with MYCN knock-down and over-expression systems to examine the effect of MYCN expression changes on gene methylation, employing both candidate gene and genome-wide assays. We show that MYCN interacts with DNA methyltransferases and is recruited to the promoter region of RASSF1A. However, using four model systems, we showed that long-term silencing of MYCN induces only a small loss of DNA methylation at the RASSF1A promoter in MYCN amplified neuroblastoma cell lines and over-expression of MYCN does not induce any DNA methylation, suggesting that MYCN is not critical for DNA hypermethylation in neuroblastoma.
© 2012 Wiley Periodicals, Inc.

Entities:  

Keywords:  DNA hypermethylation; MYCN; epigenetics; neuroblastoma

Mesh:

Substances:

Year:  2012        PMID: 23280764     DOI: 10.1002/mc.21994

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  5 in total

1.  Genome-wide DNA methylation analysis identifies MEGF10 as a novel epigenetically repressed candidate tumor suppressor gene in neuroblastoma.

Authors:  Jessica Charlet; Ayumi Tomari; Anthony R Dallosso; Marianna Szemes; Martina Kaselova; Thomas J Curry; Bader Almutairi; Heather C Etchevers; Carmel McConville; Karim T A Malik; Keith W Brown
Journal:  Mol Carcinog       Date:  2016-11-29       Impact factor: 4.784

2.  MYCN is a novel oncogenic target in adult B-ALL that activates the Wnt/β-catenin pathway by suppressing DKK3.

Authors:  Desheng Kong; Linlin Zhao; Lili Sun; Shengjin Fan; Huibo Li; Yanqiu Zhao; Zhibo Guo; Leilei Lin; Lin Cui; Ke Wang; Wenjia Chen; Yihui Zhang; Jin Zhou; Yinghua Li
Journal:  J Cell Mol Med       Date:  2018-04-19       Impact factor: 5.310

3.  Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL.

Authors:  Linlin Zhao; Chengfang Lv; Lili Sun; Qi Li; Yuhuang Wang; Min Wu; Yuying Wang; Zhibo Guo; Sicheng Bian; Desheng Kong; Leilei Lin; Yu Wang; Jin Zhou; Yinghua Li
Journal:  Invest New Drugs       Date:  2021-02-10       Impact factor: 3.850

4.  Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma.

Authors:  Marco Lodrini; Annika Sprüssel; Kathy Astrahantseff; Daniela Tiburtius; Robert Konschak; Holger N Lode; Matthias Fischer; Ulrich Keilholz; Angelika Eggert; Hedwig E Deubzer
Journal:  Oncotarget       Date:  2017-07-07

5.  Epigenetic deregulation of GATA3 in neuroblastoma is associated with increased GATA3 protein expression and with poor outcomes.

Authors:  Bader Almutairi; Jessica Charlet; Anthony R Dallosso; Marianna Szemes; Heather C Etchevers; Karim T A Malik; Keith W Brown
Journal:  Sci Rep       Date:  2019-12-12       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.